SCHEMBL31172566

SCHEMBL31172566

COc1cc(C(=O)O)cnc1Cn1cccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.49
▸ TSHR P16473 2/20 0.41
▸ LMNA P02545 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KDM5A P29375 1/20 0.39
▸ KDM2B Q8NHM5 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA4 P22748 2/20 0.38
▸ CA6 P23280 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA14 Q9ULX7 2/20 0.38
▸ CA3 P07451 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172651 0.89 LMNA (0.42) HTTTSHRLMNAUSP2GAA
SCHEMBL31172601 0.84 HTT (0.37) HTTTSHRLMNAUSP2GAA
SCHEMBL10766358 0.82 HTT (0.53) HTTTSHRLMNAGAAMAPT
SCHEMBL31172777 0.79 KAT7 (0.41) HTTLMNAUSP2GAAMAPT
SCHEMBL31172614 0.79 KAT6A (0.47) —
SCHEMBL31172762 0.79 HTT (0.56) HTTTSHRLMNAUSP2GAA
SCHEMBL31172671 0.79 HTT (0.56) HTTTSHRLMNAUSP2GAA
SCHEMBL4354266 0.76 HTT (0.56) HTTTSHRLMNAUSP2GAA
SCHEMBL31172724 0.75 HTT (0.43) HTTLMNAUSP2GAAMAPT
SCHEMBL31172640 0.73 HTT (0.56) HTTTSHRUSP2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 508/4885TSHR 3801/4885LMNA 4112/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B HTT 508/4885TSHR 3801/4885LMNA 4112/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 1323/4885TSHR 1910/4885LMNA 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback